

## Health systems, medical products and innovation:

## Challenges and priorities

EU4Health programme 2021-2027: a vision for a healthier European Union

Plenary session #3

22 January 2021

Andrzej RYS

Director - Health systems, medical products and innovation DG Health and Food Safety - European Commission

## Health systems

### Main challenges:

- COVID-19 related disruption to health systems:
  - Backlog of non-COVID care (outpatient visits, elective surgeries, diagnostic tests etc.)
  - Impact of COVID-19 on mental health
- Population ageing (associated increase in the prevalence of chronic diseases and disabilities)
- Cost pressures (demographic changes, advances in medical technology) hindering the financial sustainability of health care systems
- Burden of behavioral risk factors for health
- Gaps in care accessibility (affordability, availability)
- Health workforce shortages (doctors, nurses)
- Health inequalities (by disease, socio-economic)

- Support of the implementation (piloting) of new care models; promoting care integration;
- Supporting actions to improve **mental health** (adolescents, adults)
- Strengthening health promotion and disease prevention activities
  focus on persistent (modifiable) risk factors and the young
- Tacking health inequalities in access to care (vulnerable groups, rural areas)
- Promoting more advanced health workforce planning; support for training, upskilling and innovation (modalities of care delivery) projects
- Supporting national systems' performance through health indicator development, high-quality analysis, policy advice and knowledge brokering
- Development and support of health system **stress tests** (voluntary)
- Supporting the exchange, transfer and upscaling of best practices

# Health data and digitalization of health care

### Main challenges:

- Low availability of health data across borders
- Low interoperability of health data and systems (technical, semantic)
- Data privacy and protection
- Digital divide creating inequities in access to eHealth tools

- Supporting the digital transformation of health systems
- Creation of the European Health Data Space (EHDS) and better access to data for:
  - Better healthcare delivery (primary use)
  - Better research and policy-making (secondary use)
- Advancing the uptake of digital tools and services
- Promoting digital skills among health workers
- Enhancing European Reference Networks (ERNs)



## **Pharmaceuticals**

### Main challenges:

- Inadequate patient access to new medicines; unsustainable pricing policies
- Lessons learnt from COVID-19 re. shortages
- Lack of need-driven innovation especially in areas of unmet need
- Quality of medicines and active ingredients, green pharmaceuticals and reap the benefits of digitalization
- (Vaccines) need for swift reaction / emerging pathogens / safety and efficacy

- Repurposing existing medicines
- Support actions on shortages
- Boost the development of novel antimicrobials and address AMR.
- Support innovative clinical trials to speed up development (design and monitoring safety),
- Foster international convergence (inspections, ICH, Eur.Pharm)
  eProduct information
- Foster the development of environmentally-friendly production and disposal of medicines;
- Support actions to enhance affordability, (e.g best practice exchanges on pricing, reimbursement)
- (Vaccines) Strengthening post-marketing surveillance, tackling vaccine misinformation



## Blood, tissues and cells

### Main challenges:

- Blood and transplants are essential to support public health
- Need for national stockpiling of essential crisis relevant products at Union level including plasma
- Supporting national systems and sustainable and safe supply of such substances

- Strengthen the oversight systems in blood and transplant services
  - Upscaling and provide sustainable development of real-world data registries in transplant and transfusion
  - Develop organizational flexibility in EU transplant programs
  - Increase supply of blood, plasma and plasmaderived products.



# Health technology assessment (HTA)

### Main challenges:

- Facilitate patient access to innovative health technologies across the EU
- Promote innovation with added value
- Efficient and robust HTA at national and EU level (reduce duplication, pool resources and expertise)
- Address challenges causes by pandemics like COVID-19 (need for timely evaluation of effectiveness of COVID-19 treatments and diagnostics)

- Support the preparation and implementation of the new EU framework for HTA:
  - High-quality, timely HTA reports
  - Transparent system
  - Project-type cooperation → permanent
  - Support to IT infrastructure



## **Medical Devices**

### Main challenges:

- Improving the availability, accessibility and affordability of medical devices and critical medical products, esp. in crisis situations;
- Effective implementation of the new Medical Devices Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR)

- Encouraging sustainable production, supply, procurement and management of critical medical devices
- Monitor shortages of critical medical devices, coordinate actions and response
- Setup and management of support infrastructures (EUDAMED, Expert Panels etc)
- Promoting cooperation across Member States



## Conclusions – overview:

#### Health systems

- Health promotion and disease prevention activities
- Mental health
- Health workforce planning; training, upskilling and innovation
- Support (piloting) of new care models; promoting care integration;
- Tacking health inequalities (vulnerable groups, rural areas)
- Health indicator development, analysis and knowledgebrokering
- Health system stress tests (voluntary)
- Exchange, transfer and upscaling of best practices

#### · eHealth and digitalisation of health care

- Creation of the *European Health Data Space*
- Advancing the uptake of digital tools,
- promoting digital skills(health workers)
- Enhancing European Reference Networks

#### Pharmaceuticals

- Support actions to fix medicine shortages
- Tacking AMR
- Support innovative clinical trials
- Foster **international convergence** (inspections, *ICH*, *Eur.Pharm*)
- Environmentally-friendly production and disposal of medicines
- Best practice exchanges on pricing, reimbursement
- (Vaccines) strengthening post-marketing surveillance, tackling misinformation

#### Blood, tissues and cells

Stronger oversight systems, real-world data registries (transplant, transfusion)

#### Health technology assessment

Implementation of HTA framework

#### Medical Devices

- MDR implementation
- IDVR implementation

# Thank you

Feedback/ideas? → Join one of the breakout sessions @ 11:10 AM (running in parallel)

#### A) Health systems

- Mod: Maya MATTHEWS (DG SANTE),
- Rapporteur: **Yvette AZZOPARDI** (*EU4Health* Task Force)

#### B) Medicines, vaccines and medical devices

- Mod: Anna Eva AMPELAS (DG SANTE),
- Rapporteur: Ana BURGOS GUTIERREZ (EU4Health Task Force)

Contact: Andrzej.RYS@ec.europa.eu

